Crypto exchange Bullish targets $4.23 billion valuation in U.S. listing
The company has launched its IPO roadshow and wants to raise up to $629.3 million by offering 20.3 million shares priced between $28 and $31 each.
The crypto exchange plans to list on the New York Stock Exchange under the ticker symbol "BLSH".
J.P.Morgan, Jefferies and Citigroup (NYSE:C) are serving as the lead underwriters for the offering.
Related articles
Crypto exchange Bullish targets $4.23 billion valuation in U.S. listing
Victoria's Secret Exposed: The Warning Sign Behind the Stock's 52% Collapse
Apollo economist warns: AI bubble now bigger than 1990s tech mania
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
10 minutes ago
- Business Wire
Alcon Agrees to Acquire STAAR Surgical
GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer ® Lens (ICL), today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire STAAR. The acquisition includes the EVO family of lenses (EVO ICL™) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism. Under the terms of the agreement, Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, 2025. The transaction represents a total equity value of approximately $1.5 billion. 'With the number of high myopes rising globally, the acquisition of STAAR enhances our ability to offer a leading surgical vision correction solution for those who are not ideal candidates for other refractive surgeries such as LASIK,' said David Endicott, CEO of Alcon. 'This transaction will allow us to provide treatment options across the full spectrum of myopia—from contact lenses to surgical interventions—reinforcing our commitment to addressing the most significant needs in eye care.' An estimated 50% of the world will be myopic by 2050 and today nearly 500 million people are considered high myopes. 1 With its innovative design, the EVO family of ICLs are implantable lenses that address a wide range of vision correction needs, including myopia with and without astigmatism, through a minimally invasive procedure that is reversible. The EVO family of ICLs are implanted between the iris (the colored part of the eye) and the natural crystalline lens during a procedure that does not remove corneal tissue. 'We believe the transaction with Alcon represents the best path forward and provides the greatest value for STAAR shareholders,' said Stephen Farrell, CEO of STAAR. 'As we've shared, fluctuating demand in China over the past two years has continued to create significant headwinds for STAAR as a standalone company. I'm proud of our team's efforts to address recent challenges, but there is more work to do. As a significantly larger company, Alcon has the capabilities and scale to accelerate EVO ICL adoption and bring our innovative technology to more surgeons and patients worldwide.' Dr. Elizabeth Yeu, Chair of the STAAR Board of Directors, said, 'The STAAR Board is committed to maximizing value for shareholders. We have determined that this carefully negotiated transaction is in the best interest of STAAR shareholders as it delivers immediate and certain value at a significant premium, value that exceeds what we believe could be achieved under STAAR's standalone strategy.' The transaction is not subject to a financing condition. Alcon intends to finance the transaction through the issuance of short- and long-term credit facilities. The transaction is anticipated to close in approximately six to 12 months, subject to customary closing conditions, including regulatory approval and approval by STAAR's shareholders. The transaction is expected to be accretive to earnings in year two. The Boards of Directors of Alcon and STAAR have each unanimously approved the transaction. Morgan Stanley & Co. LLC is serving as financial advisor to Alcon, and Gibson, Dunn & Crutcher LLP is serving as legal advisor to Alcon. Citi is serving as the exclusive financial advisor to STAAR, and Wachtell, Lipton, Rosen & Katz is serving as legal advisor to STAAR. As previously announced, STAAR will release financial results for its second quarter that ended June 27, 2025, on Wednesday, August 6, 2025, after the market close. Given the pending acquisition by Alcon, STAAR will not host a conference call in conjunction with earnings. Forward-looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the potential transaction between Alcon and STAAR and the expected timing, impacts and benefits thereof, Alcon's and STAAR's business strategies, performance, market adoption and estimates of market size. In some cases, you can identify forward-looking statements by terms such as 'aim,' 'anticipate,' 'approach,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'goal,' 'intend,' 'look,' 'may,' 'mission,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'pursue,' 'should,' 'target,' 'will,' 'would,' or the negative thereof and similar words and expressions. Forward-looking statements are based on Alcon's and STAAR's management's current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions. The following factors could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: (i) the proposed merger may not be completed in a timely manner or at all, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect STAAR or the expected benefits of the proposed merger or that the approval of STAAR's stockholders is not obtained; (ii) the failure to realize the anticipated benefits of the proposed merger; (iii) the possibility that competing offers or acquisition proposals for STAAR will be made; (iv) risks that third parties and/or STAAR stockholders may oppose consummation of the proposed merger on the proposed terms or at all; (v) the possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger, including in circumstances which would require either party to pay a termination fee; (vii) the effect of the announcement or pendency of the merger on STAAR's ability to retain and hire key personnel, STAAR's ability to retain key customers, suppliers or distributors or its operating results and business generally, (viii) there may be liabilities related to the merger that are not known, probable or estimable at this time or unexpected costs, charges or expenses; (ix) the merger may result in the diversion of management's time and attention to issues relating to the merger; (x) there may be significant transaction costs in connection with the merger; (xi) legal proceedings may be instituted against STAAR following the announcement of the merger, which may have an unfavorable outcome; and (xii) STAAR's stock price may decline significantly if the merger is not consummated. In addition, a number of other important factors could cause actual future results and other future circumstances to differ materially from those expressed in any forward-looking statements, including but not limited to those important factors discussed under the heading 'Risk Factors' contained in Alcon's Annual Report on Form 20-F for the fiscal year ended December 31, 2024 and in STAAR's Annual Report on Form 10-K for the fiscal year ended December 27, 2024, each as filed with the Securities and Exchange Commission ('SEC'), as such factors may be updated from time to time in such company's other filings with the SEC, accessible on the SEC's website at and the Investor Relations section of STAAR's website at and Alcon's website at All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, neither Alcon nor STAAR undertake any obligation to publicly update or review any forward-looking statement, whether because of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing Alcon's or STAAR's views as of any date subsequent to the date of this press release. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer ® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL's are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit To learn more about STAAR, visit Important Safety Information for the EVO Family of ICLs The EVO Visian ICL Lens is intended for the correction of moderate to high nearsightedness. EVO Visian ICL and EVO Visian TICL surgery is intended to safely and effectively correct nearsightedness between -3.0 D to -15.0 D, the reduction in nearsightedness up to -20.0 D and treatment of astigmatism from 1.0 D to 4.0 D. If patients have nearsightedness within these ranges, EVO Visian ICL surgery may improve distance vision without eyeglasses or contact lenses. Because the EVO Visian ICL corrects for distance vision, it does not eliminate the need for reading glasses, patients may require them at some point, even if they have never worn them before. Implantation of the EVO Visian ICL is a surgical procedure, and as such, carries potentially serious risks. Patients should discuss the risks with their eye care professional. Complications, although rare, may include need for additional surgical procedures, inflammation, loss of cells from the back surface of the cornea, increase in eye pressure, and cataracts. For additional information with potential benefits, risks and complications please visit Additional Information This press release may be deemed solicitation material in respect of the proposed acquisition of STAAR. A special stockholder meeting will be announced soon to obtain stockholder approval in connection with the proposed merger. STAAR expects to file with the SEC a proxy statement and other relevant documents in connection with the proposed merger. Investors of STAAR are urged to read the definitive proxy statement and other relevant materials carefully and in their entirety when they become available because they will contain important information about the Company and the proposed merger. Investors may obtain a free copy of these materials (when they are available) and other documents filed by STAAR with the SEC at the SEC's website at and at STAAR's website at No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. Participants in the Solicitation Alcon, STAAR and certain of their respective directors, executive officers and other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in connection with the proposed merger. Information regarding Alcon's directors and executive officers is contained in Alcon's annual report on Form 20-F for its fiscal year ended December 31, 2024, which was filed with the SEC on February 25, 2025. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of STAAR's stockholders in connection with the proposed merger will be set forth in STAAR's definitive proxy statement for its special stockholder meeting. Additional information regarding these individuals and any direct or indirect interests they may have in the proposed merger will be set forth in the definitive proxy statement when and if it is filed with the SEC in connection with the proposed merger. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Brien A Holden at al. Ophthalmology. 2016 May;123(5):1036-42. Connect with us on Facebook LinkedIn
CBS News
11 minutes ago
- CBS News
Mario Lemieux's bid to buy back the Penguins is not close to estimated team value, report says
Mario Lemieux's bid to buy back the Pittsburgh Penguins does not come close what the team's estimated value is likely worth, according to a new report. Earlier this summer, it was reported that Lemieux, along with Ron Burkle and David Morehouse, were interested in buying the team back from the Fenway Sports Group, who purchased the team in 2021. Lemieux and Burkle sold the Penguins to FSG for just shy of $1 billion and last month, it was reported that the Lemieux group was considering its financial options that could lead to taking control of the Penguins again at some point. A new report from Sportsnet insider Elliotte Friedman suggests that the Lemieux group's bid for the team isn't close to FSG's apparent asking price. The only thing I've heard about that so far is that they're just well below what Fenway would want to be the number," Friedman said on his 32 Thoughts podcast. DK Pittsburgh Sports reported last month that the Lemieux group was prepared to buy somewhere in the range of $1 billion for the team. The Penguins were valued at $1.75 billion in the latest Forbes rankings in the fall of 2024, which came in the midst of franchise values skyrocketing across the National Hockey League. Friedman also referenced the recent $1.8 billion sale of the Tampa Bay Lightning, suggesting that price point could be "where the Penguins would want to be."
WIRED
11 minutes ago
- WIRED
Best HelloFresh Coupons and Promo Codes for August 2025
Get up to 55% off and free meal boxes using a HelloFresh coupon code today. Discover our best codes and discounts to let you save time and money. All products featured on WIRED are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. Leveraging meal kit coupons is the extreme couponing of our times—a capitalism hack-a-thon right up there with trial yoga classes and attempting to cancel your Adobe subscription. Meal kits like HelloFresh have always been a better deal than they get credit for, even at full price: It's actually hard to recreate meal kit meals for less than you can get the recipes delivered to your home. But it's especially worth it when you can find a HelloFresh coupon, promo code, or discount at more than half off. I'll admit I wasn't that sold on HelloFresh when I first tried it most of a decade ago. It was useful, it got me out of my staid routines, but I wasn't impressed with the selection. It felt a little basic. But lately? Honestly, it's kinda cosmopolitan these days, after expanding to a dozen countries and absorbing the supply networks from multiple other meal plans. When I last tested the HelloFresh meal kit (7/10, WIRED Recommends), I was surprised to find myself cooking credible home renditions of ramen, ponzu-plum beef stir fry, and Southwest-accented pork roasts. And when I'm able to pick up a HelloFresh discount code, it's generally less than I'd spend on groceries anyway. So it's a good moment to try out a lifestyle where the food comes in the mail. Get 50% Off and up to 10 Free Meals as a New HelloFresh Customer Right now, new and returning customers can take advantage of a HelloFresh discount code offering 50% off your first meal kit box plus a free item each week. Enter your email as part of the signup process, and you'll be auto-subscribed to an email with even more offers for both new and existing customers. Plus, new customers can get up to 55% off and extra free breakfasts, desserts, and other items with other secret discounts. HelloFresh Student and Discount: 55% Off, Free Shipping, Plus Extra 15% Off Education Discounts Available via UNiDAYS HelloFresh meal kits are pretty amenable to dorm life when ordering the ready-to-eat meals—or just saving time during grad school instead of ordering pizza, by letting the Internet do your shopping and meal planning. But student budgets tend to be tight, of course. And so there are steeply discounted HelloFresh coupon codes specifically for students. Follow the link here for a HelloFresh education promo code offering 55% off your first box, free shipping, and a continuing discount of 15% off for the first year. Discounts also apply to teachers who've never tried HelloFresh. Educators and school employees can get up to 12 free meals spread out across 3 boxes, plus free shipping. Click here for the HelloFresh promo code, or go here for more information about educator discounts. Note that the student and educator discounts don't combine with any other HelloFresh discounts or promotions. Special Hero Discount for Military, Veterans, and Healthcare Workers Military discounts are a long tradition in America. HelloFresh also offers hero discount programs for first responders, health professionals, and military personnel. Heroes also get excellent discounts that include 55% off the first order, free shipping, and 15% off for the first year of HelloFresh delivery boxes. This program is open to nurses, hospital employees, EMTs, active military, veterans, and first responders. First responders include law enforcement, 911 dispatch, and firefighters. Click here to see if you're eligible, or follow this link for more information about HelloFresh hero discounts. Note that the hero discounts don't combine with any other HelloFresh promo codes. Give $40, Get $10 With the HelloFresh Referral Program Already a HelloFresh subscriber? You're still eligible for discounts if you pass along subscription information to your friends. Here's how: Send your friends a $40 discount for their own affordable meal kits. Once they sign up using your HelloFresh referral code, you'll also get a $10 credit on your next delivery. These discounts stack. So if you sign up multiple friends with your referral code, you get multiple $10 discounts. Check out the HelloFresh meal kit referral program here. Take Advantage of HelloFresh Come Back Offers Some of these discounts are only available to new HelloFresh customers. But there's a hack to getting discounts anyway. After you pause or cancel your subscription, check your inbox after the next few days or weeks. Often, you'll get HelloFresh coupon codes for discounts. Typical HelloFresh 'come-back' offers after a canceled subscription include: $100 to $180 off (spread out over several meal boxes), free shipping on the first box (after re-subscribing), free items such as dessert, breakfast, or an extra protein per meal, or a free meal box is offered after a break. Typical retention offers, for when customers try to cancel, include: 40% off the next box, if you decide not to cancel, or 25% off the next two meal kits. None of this is failsafe, of course, offers vary for each customer. But as with magazine subscriptions, sometimes canceling, or trying to cancel, will lead to a good discount offer from a company eager to keep your business. When to Save the Most on HelloFresh Subscriptions HelloFresh almost always has some sort of deal going, whether to bring in new customers with an especially choice HelloFresh coupon, or bring back previous customers with HelloFresh discount codes and retention offers. But summer tends to be one of the times they offer the steepest discounts, including 10 free meals across several boxes, complimentary appetizers, free ready-made items, or free shipping on select boxes. The other big times for HelloFresh coupon codes are around Black Friday and the end of the year. HelloFresh often launches limited-edition holiday meal boxes and themed meal kits, not to mention discounts for returning customers looking to cook more at home as part of New Year's resolutions.
